<DOC>
	<DOCNO>NCT00047164</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody anti-cytotoxic T-lymphocyte-associated antigen-4 locate cancer cell either kill deliver cancer-killing substance without harm normal cell . PURPOSE : This phase II trial study anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody see well work treat patient lymphoma colon cancer respond vaccine therapy .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy Treating Patients With Lymphoma Colon Cancer That Has Not Responded Vaccine Therapy</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine toxicity anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody patient follicular mantle cell lymphoma , colon cancer , prostate cancer refractory vaccine therapy . ( part I ) ( prostate cancer mantle cell lymphoma close accrual 3/10/2005 ; colon cancer close accrual 9/28/05 ) - Determine toxicity drug escalate dos patient follicular lymphoma . ( part II ) - Determine toxicity drug escalate dos patient non-Hodgkin 's lymphoma Hodgkin 's lymphoma . ( part III ) Secondary - Determine ability drug increase tumor-specific T-cell response patient . - Determine ability drug produce clinical tumor response patient . - Determine effect drug suppressor T-cell population ( CD4+ CD25+ cell ) patient . OUTLINE : This pilot , partial dose-escalation study . - Part I ( patient prostate colon cancer follicular mantle cell lymphoma ) ( prostate cancer mantle cell lymphoma close accrual 3/10/2005 ; colon cancer close accrual 9/28/05 ) : Patients receive anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody ( MDX-CTLA4 ) IV 90 minute day 1 . Treatment repeat every 28 day 4 course absence disease progression unacceptable toxicity . - Part II ( dose-escalation ) ( patient follicular lymphoma ) : Patients receive MDX-CTLA4 part I . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos MDX-CTLA4 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . - Part III ( dose-escalation* ) ( patient non-Hodgkin 's Hodgkin 's lymphoma ) : Patients receive MDX-CTLA4 part II . NOTE : No dose-escalation lymphoma patient previously treat allogeneic stem cell transplantation . Patients follow every month . PROJECTED ACCRUAL : A total 89 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm prostate cancer ( close accrual 3/9/2005 ) Prior therapy protocol NCI00C0137 NCI00C0154 Progressive disease ( 2 consecutively rise PSA level , new bone scan lesion , progression soft tissue ) PSA least 5 ng/mL Progressive androgenindependent disease Disease progression least 4 week flutamide withdrawal OR Disease progression least 6 week bicalutamide nilutamide withdrawal OR Histologically confirm follicular mantle cell nonHodgkin 's lymphoma ( mantle cell lymphoma close accrual 3/9/2005 ) Prior therapy protocol NCI00C0133 , NCI01C0169 , NCI00C0050 Progressive disease standard treatment Relapsed disease OR Histologically confirm colon cancer ( colon cancer close accrual 9/28/05 ) Prior therapy protocol NCI99C0023 Progressive disease OR Histologically confirm nonHodgkin 's lymphoma Hodgkin 's lymphoma Progressive disease standard treatment No curative therapy exist Prior allogeneic stem cell transplantation match sibling match unrelated donor aggressive lymphoma allow Last infusion allogeneic cell ( either hematopoietic stem cell donor lymphocyte ) must occur &gt; 90 day prior study enrollment No standard therapy available refuse therapy No symptomatic rapidly progressive malignancy require therapy No symptomatic CNS metastases PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 80100 % Life expectancy More 2 month Hematopoietic WBC least 2,500/mm^3 Granulocyte count least 1,500/mm^3 Platelet count least 50,000/mm^3 Hemoglobin least 10 g/dL Hematocrit least 30 % Hepatic Bilirubin great 3.0 mg/dL ( unless due Gilbert 's disease ) SGOT SGPT great 3 time upper limit normal Hepatitis B surface antigen negative Hepatitis C antibody negative Renal Creatinine great 2.0 mg/dL Immunologic HIV negative Rheumatoid factor negative history evidence arthritis Antinuclear antibody ( ANA ) titer great 1:80 history clinical sign symptom connective tissue disease No prior active autoimmune disease ( e.g. , uveitis , rheumatoid arthritis , lupus erythematosus , autoimmune hemolytic anemia , ulcerative hemorrhagic colitis , endocrine disorder [ e.g. , thyroiditis , hyperthyroidism , hypothyroidism , autoimmune hypophysitis/hypopituitarism , adrenal insufficiency ] , sarcoid granuloma , myasthenia gravis , polymyositis , GuillainBarre syndrome ) No positive antibody titer autoimmune disease Rheumatoid factor positive allow unless ANA titer great 1:80 history clinical sign symptom connective tissue disease No active infection Other No active malignancy within past 5 year except adequately treat squamous cell basal cell skin cancer , carcinoma situ cervix , superficial bladder cancer Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 4 month study participation PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics Recovered prior vaccine therapy No prior anticytotoxic Tlymphocyteassociated antigen4 monoclonal antibody ( MDXCTLA4 ) patient part I study Patients part II study may 4 prior treatment MDXCTLA4 No concurrent vaccine therapy No concurrent infliximab Chemotherapy At least 4 week since prior cytotoxic chemotherapy No concurrent mercaptopurine , methotrexate , cyclophosphamide Endocrine therapy See Disease Characteristics At least 4 week since prior steroid No concurrent systemic , inhale , topical steroid Radiotherapy At least 4 week since prior radiotherapy Surgery At least 4 week since prior major surgery Other Prior intervene therapy prostate cancer , nonHodgkin 's lymphoma colon cancer allow No concurrent investigational therapy No concurrent immunosuppressant ( e.g. , cyclosporine analog )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>stage I adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage I adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage I adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage I adult Burkitt lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>stage I adult Hodgkin lymphoma</keyword>
	<keyword>stage II adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage I adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>stage I marginal zone lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage I small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage I adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage I cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage II adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
</DOC>